Benznidazole-loaded polymeric nanoparticles for oral chemotherapeutic treatment of Chagas disease.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorSousa, Lucas Resende Dutra-
Autor(es): dc.creatorDuarte, Thays Helena Chaves-
Autor(es): dc.creatorXavier, Viviane Flores-
Autor(es): dc.creatorMercês, Aline Coelho das-
Autor(es): dc.creatorVieira, Gabriel Maia-
Autor(es): dc.creatorMartins, Maximiliano Delany-
Autor(es): dc.creatorCarneiro, Cláudia Martins-
Autor(es): dc.creatorSantos, Viviane Martins Rebello dos-
Autor(es): dc.creatorSantos, Orlando David Henrique dos-
Autor(es): dc.creatorVieira, Paula Melo de Abreu-
Data de aceite: dc.date.accessioned2025-08-21T15:25:54Z-
Data de disponibilização: dc.date.available2025-08-21T15:25:54Z-
Data de envio: dc.date.issued2025-01-29-
Data de envio: dc.date.issued2025-01-29-
Data de envio: dc.date.issued2023-
Fonte completa do material: dc.identifierhttps://www.repositorio.ufop.br/handle/123456789/19645-
Fonte completa do material: dc.identifierhttps://doi.org/10.3390/pharmaceutics16060800-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1014484-
Descrição: dc.descriptionChagas disease (CD) is a worldwide public health problem. Benznidazole (BZ) is the drug used to treat it. However, in its commercial formulation, it has significant side effects and is less effective in the chronic phase of the infection. The development of particulate systems containing BZ is therefore being promoted. The objective of this investigation was to develop polymeric nanoparticles loaded with BZ and examine their trypanocidal impact in vitro. Two formulas (BNP1 and BNP2) were produced through double emulsification and freeze drying. Subsequent to physicochemical and morphological assessment, both formulations exhibited adequate yield, average particle diameter, and zeta potential for oral administration. Cell viability was assessed in H9C2 and RAW264.7 cells in vitro, revealing no cytotoxicity in cardiomyocytes or detrimental effects in macrophages at specific concentrations. BNP1 and BNP2 enhanced the effect of BZ within 48 h using a treatment of 3.90 μg/mL. The formulations notably improved NO reduction, particularly BNP2. The findings imply that the compositions are suitable for preclinical research, underscoring their potential as substitutes for treating CD. This study aids the quest for new BZ formulations, which are essential in light of the disregard for the treatment of CD and the unfavorable effects associated with its commercial product.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsaberto-
Direitos: dc.rightsThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Fonte: PDF do artigo.-
Palavras-chave: dc.subjectBenznidazole-
Palavras-chave: dc.subjectChagas disease-
Palavras-chave: dc.subjectFormulations-
Palavras-chave: dc.subjectPolymeric nanoparticles-
Palavras-chave: dc.subjectTrypanocidal activity-
Título: dc.titleBenznidazole-loaded polymeric nanoparticles for oral chemotherapeutic treatment of Chagas disease.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.